Amendment of Solicitation/Modification of Contract, dated as of July 26, 2022 by and between the Company and Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

1 CONTRACT ID CODE

PAGE OF PAGES

1

6

2. AMENDMENT/MODIFICATION NO.

P00008

3. EFFECTIVE DATE

See Block 16C

4. REQUISITION/PURCHASE REQ. NO.

5. PROJECT NO. (If applicable)

6. ISSUED BY

CODE

ASPR-BARDA

7. ADMINISTERED BY (If other than Item 6)

CODE

ASPR-BARDA

ASPR-BARDA

200 Independence Ave., S.W.

Room 640-G

Washington DC 20201

ASPR-BARDA

US DEPT OF HEALTH & HUMAN SERVICES BIOMEDICAL

ADVANCED RESEACH & DEVELOPMENT AUT 200

INDEPENDENCE AVE, S.W.

Washington DC 20201

8, NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

(x)

9A. AMENDMENT OF SOLICITATION NO.

T2 BIOSYSTEMS, INC. 1512719

Attn: ALEC BARCLAY

T2 BIOSYSTEMS, INC.

101 HARTWELL AVE

LEXINGTON MA 02421

9B. DATED (SEE ITEM 11)

x

10A. MODIFICATION OF CONTRACT/ORDER NO.

75A50119C00053

CODE       1512719

FACILITY CODE

10B. DATED (SEE ITEM 13)

09/30/2019

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

☐

The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers                                  ☐ is extended      ☐ is not extended.

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning                          copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA (If required)

See Schedule

13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

CHECK ONE

A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

X

C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF

FAR Part 43.103(a) - Bilateral Modification

D. OTHER (Specify type of modification and authority)

E. IMPORTANT:   Contractor        ☐ is not       ☒ is required to sign this document and return                          1                 copies to the issuing office.

9 Option TWO B (2B) Period:

0.00

15A. NAME AND TITLE OF SIGNER (Type or Print)

16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)

Alec Barclay

Chief Operations Officer

RICHARD A. HALL

15B. CONTRACTOR/OFFEROR

15C. DATE SINGED

16B. UNITED STATES OF AMERICA

16C. DATE SIGNED

/s/ Alec Barclay

/s/ Richard A. Hall – S.

Date: 2022.07.26

(Signature of person authorized to sign)

07/26/2022

(Signature of Contracting Officer)

17:16:43 -04’00’

Previous edition unusable

STANDARD FORM 30 (REN 11/2016)

Prescribed by GSA FAR (48 CFR) 53.243

CONTINUATION SHEET

REFERENCE NO. OF DOCUMENT BEING CONTINUED

7 5A50119C00053/P00008

PAGE     OF

2

6

NAME OF OFFEROR OR CONTRACTOR

T2 BIOSYSTEMS, INC. 1512719

ITEM NO.

(A)

SUPPLIES/SERVICES

(B)

QUANTITY

(C)

UNIT

(D)

UNIT PRICE

(E)

AMOUNT

(F)

Continue T2Biothreat verification testing and initiate validation testing. Produce a functioning Beta instrument. Complete initial optimization studies and demonstrate required sensitivity with a manual process. Initiate T2Resistance Panel verification and clinical Validation studies Amount: $4,389,160.00(Option Line Item)

NSN 7540-01-152-8067

OPTIONAL FORM 336 (4-86)

Sponsored by GSA

FAR (48 CFR) 53.110

Contract No.

75A50119C00053

Modification No. P00008

Continuation Sheet

Block 14

Page 3 of 6

The contract includes optional, cost reimbursement CLINs 0002 through 0007. The Government may exercise Option Periods in accordance with FAR 52.217-9 Option to Extend the Term of the Contract (March 2000), as set forth in Section I of the contract.

The contract includes optional services, cost reimbursement CLIN 0008. The Government may exercise Option Services in accordance with FAR 52.217-8 Option to Extend Services, as set forth in Section I of the contract.

Unless the government exercises its option pursuant to the option clause contained in ARTICLE 1.2, the contract consists only of the Base Work segment specified in the Statement of Work as defined in SECTION C and F, for the price set forth in ARTICLE B.2 of the contract.

The Government may modify the contract unilaterally and require the contractor to provide supplies and services for Option Periods listed below, in accordance with FAR 52.217-9.

If the Government decides to exercise an option(s), the Government will provide the Contractor a preliminary written notice of its intent as referenced in the clause. Specific information regarding the time frame for this notice is set forth in the OPTION CLAUSE Article in SECTION G of this contract. The estimated cost of the contract will be increased as set forth below:

Contract No.

75A50119C00053

Modification No. P00008

Continuation Sheet

Block 14

Page 4 of 6

Option

CLIN

Period of
Performance

Supplies/Services

BARDA

Estimated Not

to Exceed

T2 Estimated

Not to Exceed

Overall Total

Estimated Not

to Exceed

1

0002

09/14/2020 - 10/15/2021

Option 1 Period: Optimize the T2 Biothreat Panel to meetrequirements on the T2Dx device.

Design, build, and optimizeT2Nxt subsystems, and integrate those subsystems into a working device.

Optimize the T2AMR Panel to detect targets

$10,495,783

$3,925,669

$14,421,452

2A

0003

09/30/2021 - 03/31/2022

Option 2A Continue T2Biothreat verification testing and initiate validation testing. Produce a functioning Beta instrument. Complete initial optimization studies and demonstrate required sensitivity with a manual process. Initiate T2Resistance Panel verification and clinical validation studies

$6,357,371

$2,087,418

$8,444,789

2B

0004

04/01/2022-

09/16/2022

Option 2B Continue T2Biothreat verification testing and initiate validation testing. Produce a functioning Beta instrument. Complete initial optimization studies and demonstrate required sensitivity with a manual process. Acquire and establish requirements for T2Biothreat Panel on T2Nxt.

$4,389,160

$2,960,502

$7,349,662

3

0005

[***]- [***]

Option 3 Period: [***]

$[***]

$[***]

$[***]

Contract No.

75A50119C00053

Modification No. P00008

Continuation Sheet

Block 14

Page 5 of 6

4

0006

[***]- [***]

Option 4 Period: [***]

$[***]

$[***]

$[***]

5

0007

[***]- [***]

Option 5 Period:  [***]

$[***]

$[***]

$[***]

6

0008

08/01/2024-

03/25/2025

Option 6 Period:  [***]

$[***]

$[***]

$[***]

Contract No.

75A50119C00053

Modification No. P00008

Continuation Sheet

Block 14

Page 6 of 6

Optional

Services

0009

[***]- [***]

Option 7 Period:  [***]

$[***]

$[***]

$[***]

TOTALS

Only option years

$[***]

$[***]

$[***]

TOTALS

Base+ options

$68,950,964

$[***]

$[***]